Sildenafil (H2S and NO donor) for Fetal Growth Restriction, A Promise not Fulfilled

During the Paris Redox 2020 Congress, Dr. Wessel Ganzevoort from Academisch Medisch Centrum Universiteit Amsterdam, The Netherland will give a presentation entitled "Sildenafil (H2S and NO donor) for Fetal Growth Restriction, A Promise not Fulfilled".

Prof. Ganzevoort highlights: Sildenafil was proposed to improve fetal growth in severe early-onset uteroplacental insufficiency. Uteroplacental insufficiency has its root in the first trimester of physiological pregnancy when the uteroplacental vascular unit transforms to a low-resistance high volume flow system. However, retained vascular contractility due to deficient vascular remodeling is the pathological pendant of that process leading to inadequate nutrient and oxygen transfer, necessary for a thriving fetus. Retained vascular contractility can be the starting point for a medical intervention to lower uteroplacental resistance and improve placental exchange. Among the candidates are H2S-donors, NO-donors, and PDE5-inhibitors (sildenafil). Based on ample animal data and some human data showing improved fetal growth and better pregnancy outcomes there was a creep into practice in cases with a dismal prognosis. In a combined approach several trials were designed in synchrony: The STRIDERs. This presentation will highlight the unexpected findings from the Dutch STRIDER.

Paris Redox 2020 Congress
October 8-9, 2020 - Paris, France
www.isanh.net